Upload
dieter-fassnacht-phd-pmp
View
524
Download
6
Embed Size (px)
Citation preview
1
Grifols’ North Fractionation FacilityFOYA Winner – Project Execution
Dieter Fassnacht
2
AgendaIntroduction to GrifolsNorth Fractionation Facility Project- Key Goals and AccomplishmentsHighlights in Project Execution- Drive Development of Key Technologies- Perform Detailed Feasibility Studies- Design Competition to Find A&E Partner- Establish & Maintain Strong Project Team- Control Project with Devoted Steering Committee
- Modular Construction- Functional Testing During Construction- Leveraging Construction & Commissioning for IOQ- Engineering Test Runs with PlasmaOther Highlights- Reduced Risk to Product Quality- Manufacturing Efficiencies- Facility Integration
3
Grifols Overview
2 TESTING POOLING3 FRACTIONATION4 PURIFICATION5 FILLING61 COLLECTION
Plasma Fractionation Technology
Grifols is the world’s third largest producer of plasma derived medicines.We are dedicated to developing innovative healthcare products and services while maintaining the highest ethical standards for patients and employees across the globe.The company has 12,000 employees worldwide committed to serving patients affected by life-threatening conditions.Manufacturing sites producing plasma-derived pharmaceuticals are located in Parets del Vallès, Spain (close to Barcelona), Clayton, NC and Los Angeles.
Recent Acquisitions2011: Grifols acquires Talecris Biotherapeutics for $ 3.4 billion2014: Grifols acquires Novartis Diagnostics Unit for $ 1.7 billion
4
North Fractionation Facility (NFF)
Key FiguresLocation: Clayton, NC, US
Size: 150,000 sq. ft.
Project Cost: $ 342.6 million
Construction Duration: 24 month
Status: Awaiting FDA PAI
5
Provide high-throughput manufacturing facility with minimal risk to product quality- World’s largest batch size of 9,000 L and annual capacity of up to 6 MML- Maximized closed processing and incorporated high level of automation
Maximize yields while maintaining product quality- Optimized processing methods and decreased physical losses
Lower long-term operational costs- Minimized clean room production space with no cold processing rooms.- Reduced labor costs due to scale, automation and improved technology
Deliver the facility in an aggressive timeframe and under budget
North Fractionation Facility (NFF)
Project Goals & Achievements
Project JustificationIncrease companies fractionation capacity to fulfill patient demands
6
Drive Development of Key Technologies
Centrifugation (GEA Westfalia)
Precipitation• 1995: Precipitation optimization studies• Long-term data collection and statistical evaluation to
optimize process• 2008: Confirmation at 1,000 L manufacturing scale
Bottle & Bag thawing and opening
• 1998: Collaboration between Bayer and Westfalia to develop unique centrifuge for fractionation
• 2000: First BSH-30 centrifuge tested• 2004: Second generation machine tested• 2007: Third generation machine tested• 2013: FDA licensure of BSH-30 centrifuge
• In-house equipment innovation by Grifols Engineering
7
Perform Detailed Feasibility Studies
New Fractionation Facility
Site (Evaluation of Utilities, Infrastructure and Building Location)• 2003: Infrastructure Feasibility Report• 2008: NFF Site Feasibility Study
• 2006: Fractionation Strategy• 2008: Report on New Fractionation
Stakeholder Approval- Manufacturing- Engineering- Technology- Quality- Regulatory Affairs
Ready to Launch Capital Project
Table of Content- Executive Summary- Process Design- Manufacturing Plant Concepts- Building Description- Utilities and Infrastructure Requirements- Development Strategy and Technology Base- Regulatory Outlook- Project Timeline- Project Cost Estimate- Open Issues and Risks
8
Design Competition to Find A&E Partner
Bid Process for Conceptual Engineering included Design Competition to
Pre-Screening• Three A&E firms were identified to be suitable partners
based on comprehensive survey of existing large scale bioscience facilities and EPCV experience
• challenge Feasibility Study• develop new concepts and ideas• assess teams, collaboration and creativity
Valuable Results included:
- Building location, orientation and size
- Vertical integration / logistics
- Creative concepts around unique process steps
Team selected Fluor as Partner for the Project
9
Establish and Maintain Strong Project Team
Collaboration with A&E firm to form “one” team
Staffing• Grifols Team maintained continuity from Conceptual
Engineering through Validation.• Project Team also included from “day one” dedicated
resources from• Plant Engineering incl. Maintenance
Supervisor and Technicians*• Production Manager and Supervisor• Technology (R&D)• Quality• Validation
Senior Management committed in Project Charter to“support the right resources at right time”“maintain critical team members and sufficient
overall staffing”
• Grifols and Fluor formed fully integrated team.
• Team worked out of Greenville, SC.• Grifols key team visited Greenville every
two weeks.
* As presented at 20th ISPE CASA Life Sciences Technology Show by Brent Noel and Detlef Kehm
10
Control Project with Devoted Steering Committee
Steering Committee- CEO- CFO- SVP Manufacturing (Site Head)- SVP R&D- SVP Corporate Compliance
Principals Meeting
- SVP Manufacturing (Site Head) - Program Director- VP Engineering - Project Director- VP Manufacturing - Finance Director- VP R&D - Supply Chain Director- VP Quality - Fluor Senior Management- VP Regulatory Affairs - MIV Management- VP Finance
NFF Team Leaders
Meets Monthly
11
Modular Construction*
* As presented at INTERPHEX™ 2013 by Detlef Kehm, “Large Scale Process Modules First in Place Technology”
Benefits for On Site Super Skid Fabrication• Controlled conditions in fabrication shop leads to higher quality and
safer environment• Reduced congestion and coordination in the building• Increased productivity due to high quality of specialty workforce• Simultaneous construction of Building including Infrastructure and
Process Modules enabling schedule compression by 4 months.• Large “off shore” pool of resources can be utilized concurrently• Standardization leads to assembly line approach
12
Functionality Testing during Construction
Construction approach• One of seven Centrifuge Piping skids was accelerated
to provide early functionality testing. This skid would also be the last one to be installed in NFF building to maximize testing duration
• Test Stand installed to provide structure for centrifuge and all utilities to enable testing.
Benefits• Significant software modifications occurred during four
months testing period while facility was still in construction leveling future resource demands.
• Only minor piping modifications confirmed thorough skid design.
Objective• Obtain head-start for functional testing and debugging
of most complicated process equipment of project• Also allowing possible last minute piping changes
to other skids .
13
Leveraging Construction & Commissioning for IOQ
Commissioning Approach
MIV (Main Instrumentation Vendor) ApproachSelection of MIV partner for entire project allowed single point of contact to perform RV (receipt verification) of instruments which included 3rd party quality inspection prior to shipment to site or fabricators
• Utilize validated database and formal protocols (FAT, commissioning) to allow leveraging for IOQ.• Commission equipment according to same system boundaries as IOQ• Use formal Project Change Control to bridge changes between verification and qualification
Asset Database• Validated database was used to populate asset attributes during construction including receipt
and installation verification• Bulk upload into site maintenance system (Maximo) upon completion of individual systems
Commissioning
IV protocols
OV protocols
Qualification
IQ protocols
OQ protocols
upload data, calibration done, project changes closed
draft procedures, testing with product, changes closed
14
Engineering Test Runs with Plasma
Benefits of Testing with Plasma• Final tweaking of parameters specifically to optimize
separation temperatures could only be executed with plasma.
• Many OQ test cases used product instead of a water / ethanol surrogate increasing confidence in successful process validation
Plasma Industry’s Challenge for Product Testing• Released plasma cannot be used for test runs due to high
costs of almost $1 MM per batch and resulting lack of final product in the market
• Pathogen Safety prohibits use of untested, released plasma
Securing Plasma for Test Runs• Over 60,000 Liters of tested plasma (not for production
use) was secured over five years to enable testing of NFF process.
15
Other Highlights: Reduced Risk to Product Quality
• Validated a closed process to eliminate contamination risk and reduce the cleanroom space
• Collaborated with Grifols Engineering to develop a robotic bottle opening system to eliminate potential plasma contact with operators (Installation of plasma bag opening system is in progress)
• Employed automation systems reducing human error and increase process reliability
16
Other Highlights: Manufacturing Efficiencies
• Effected a 100% increase in site output to 6 MML plasma per year
• Automation and equipment functionality lowered labor per liter fractionated by 40%
• Increased process yield between 8 and 15% by leveraging Grifols advanced understanding of processing human plasma
• Achieved a 31% reduction in energy per liter with closed process in ambient space
• Reduced chemical costs by $1 million annually by employing bulk chemical storage and distribution
17
Other Highlights: Facility Integration
• Produced modern sustainable facility that eliminates harsh cold work environments, while achieving excellent functional arrangements resulting in a minimization of material movement
• Contained manufacturing operations on a single level.
• Minimized cleanroom footprint to 12% of gross space
• Directing vertical transfer between levels produced simplified horizontal flow paths
• Applied broad use of windows and natural light
18
Thank you ISPE for Recognizing our Effort and Accomplishments!